Drugs / ZMA001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05967299 | Nov 2023 → Sep 2027 expected | pulmonary arterial hypertension | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZMA001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05967299 ↗ |
| Known as | BC-NKA-20008 | “ZMA001 (BC-NKA-20008)” NCT05967299 ↗ |
| Action | Inhibit | “inhibits migration of activated monocytes and macrophages” NCT05967299 ↗ |
| Modality | Monoclonal antibody | “ZMA001 is a fully human, monoclonal antibody (IgG1)” NCT05967299 ↗ |
| Route | Intravenous | “intravenous ZMA001” NCT05967299 ↗ |